Identification of LINC02310 as an enhancer in lung adenocarcinoma and investigation of its regulatory network via comprehensive analyses

Table 4 Clinical feature analysis of LINC02310 based on TCGA clinical data

Clinical features	Low	High	p₁	p₂
Gender
Female	216	60	0.831	0.776
Male	183	54
Race
American Indian or Alaska native	1	0	0.762	0.745
Asian	6	1
Black or African American	43	9
White	300	87
Age
< 55	56	15	0.878	0.803
≥ 55	328	95
TNM-stage
I	222	52	0.033	0.027
II	95	26
III	55	29
IV	21	5
T-stage
T1/T2	352	92	0.043	0.038
T3/T4/TX	47	22
N-stage
N0	268	62	0.035	0.035
N1	71	24
N2/N3/NX	60	27
M-stage
M0	265	79	0.726	0.655
M1	21	4
MX	111	29
Pack-years smoked
< 20	49	10	0.389	0.310
≥ 20	225	67

‘Low’ and ‘high’ represent the number of LADC samples where LINC02310 were low expressed and high expressed, respectively. p₁ and p₂ are the p-values of Fisher’s accurate test and Pearson’s chi-squared test, respectively

ISSN: 1755-8794